Tretinoin, cutaneous

Generic name
Tretinoin, cutaneous
Brand name
ATC Code
D10AD01
Compare …

Tretinoin, cutaneous

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No studies have been carried out into the pharmacokinetic parameters of cutaneous tretinoin in children. 

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Plantar verruca
  • Cutaneous
    • ≥ 2 years

      • Apply twice daily to the warts.

      • Expert opinion. No studies have been carried out into the use of tretinoin for warts

    • ≥ 2 years

      • Apply twice daily to the warts.

      • Expert opinion. No studies have been carried out into the use of tretinoin for warts

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Mild skin irritation, in particular at the start of the treatment (burning sensation, erythema, itching, dryness, flaky skin)

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Higher concentrations give more side effects. The tolerability of tretinoin is affected by the delivery method (alcohol or cream). The chemical stability of tretinoin is affected by light, which is why it should be applied in the evening before going to sleep.
Starting with a low concentration, lower frequency of administration and shorter contact duration can improve the tolerability.

Tretinoin is highly teratogenic. Insufficient details are known about cutaneous use during pregnancy. Cases of congenital abnormalities have been reported. Cutaneous application during pregnancy is therefore not recommended.
 

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Retinoids for topical use in acne
D10AD03
D10AD53
Peroxides
D10AE01
Antiinfectives for treatment of acne
D10AF51
D10AF01
D10AF02
D10AF51
Other anti-acne preparations for topical use
D10AX03

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Eichenfield LF, et al, Study of the efficacy and tolerability of 0.04% tretinoin microsphere gel for preadolescent acne, Pediatrics, 2010, Jun;125(6), e1316-23.
  3. Webster G, et al, A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne, Cutis, 2009, Mar;83(3), 146-54
  4. Eichenfield LF, et al, Perspectives on therapeutic options for acne: an update, Semin Cutan Med Surg, 2010, Jun;29(2 Suppl 1), 13-6
  5. Zaenglein AL, , Expert committee recommendations for acne management.. , Pediatrics, 2006, Sep;118(3), 1188-99
  6. Gollnick H, et al, Global Alliance to Improve Outcomes in Acne.Management of acne: a report from a Global Alliance to Improve Outcomes in Acne, J Am Acad Dermatol, 2003, Jul;49(1 Suppl), S1-37
  7. Bruinsma M, et al, NHG Standaard Acne (derde herziening), Huisarts Wet, 2017 (april)
  8. Zaenglein AL,, Expert committee recommendations for acne management.., Pediatrics, 2006, Sep;118(3), 1188-99

Changes

Therapeutic Drug Monitoring


Overdose